Assessment of the availability of repurposed orphan drugs in India

Assessment of the availability of repurposed orphan drugs in India

Show other versions (1)

Bibliographic Details
Main Authors:	Khujith Rajueni, Mohua Chakraborty Choudhury
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2023-01-01
Series:	PLOS Global Public Health
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529578/?tool=EBI

Similar Items

Assessment of the availability of repurposed orphan drugs in India.
by: Khujith Rajueni, et al.
Published: (2023-01-01)

Rare disease patients in India are rarely involved in international orphan drug trials
by: Monoswi Chakraborty, et al.
Published: (2022-01-01)

Rare disease patients in India are rarely involved in international orphan drug trials.
by: Monoswi Chakraborty, et al.
Published: (2022-01-01)

The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study
by: Mohua Chakraborty Choudhury, et al.
Published: (2019-11-01)

Discrepancies between FDA documents and ClinicalTrials.gov for Orphan Drug-related clinical trial data
by: Mohua Chakraborty Choudhury, et al.
Published: (2022-01-01)

Discrepancies between FDA documents and ClinicalTrials.gov for Orphan Drug-related clinical trial data.
by: Mohua Chakraborty Choudhury, et al.
Published: (2022-01-01)

Practices for accessing hormone therapy in male to female transgenders in Maharashtra, India
by: Khujith Rajueni, et al.
Published: (2022-05-01)

The role of patient organizations in the rare disease ecosystem in India: an interview based study
by: Mohua Chakraborty Choudhury, et al.
Published: (2019-05-01)

Orphan drugs in Italy: availability and time-to-access at regional level
by: Maria Lucia Marino, et al.
Published: (2023-12-01)

Availability of Orphan drugs: Basic legal issues of development and financing
by: Stojković-Zlatanović Sanja
Published: (2019-01-01)

Facilitating audits of clinical trial data using documents of the Food and Drug Administration
by: Gayatri Saberwal, et al.
Published: (2022-12-01)

Orphan drugs assessment in the centralised procedure
by: Giuseppe Nisticò
Published: (2011-01-01)

Expansion of India’s national child healthcare programme, Rashtriya Bal Swasthya Karyakram (RBSK), for rare disease management : a health policy perspective
by: Pragya Chaube, et al.
Published: (2023-06-01)

Drug repositioning or target repositioning: A structural perspective of drug-target-indication relationship for available repurposed drugs
by: Daniele Parisi, et al.
Published: (2020-01-01)

Repurposing of Plasminogen: An Orphan Medicinal Product Suitable for SARS-CoV-2 Inhalable Therapeutics
by: Anna Maria Piras, et al.
Published: (2020-11-01)

Rare diseases and orphan drugs.
by: Aronson, J
Published: (2006)

Rare diseases and orphan drugs
by: Domenica Taruscio, et al.
Published: (2011-01-01)

Orphan drugs and rare diseases /
by: Pryde, David C., editor, et al.
Published: (2014)

Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
by: Hans-Georg Eichler, et al.
Published: (2023-01-01)

Expenditure trends of orphan drugs in Serbia: 8-Year analysis of orphan drug market in Serbia
by: Pejčić Ana V., et al.
Published: (2016-01-01)

Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2
by: Yiying Xue, et al.
Published: (2023-06-01)

Health technology assessment: oncology drugs with orphan designation as an example
by: Wild Claudia
Published: (2010-10-01)

Multi-criteria decision analysis for assessment and appraisal of orphan drugs
by: Georgi Iskrov, et al.
Published: (2016-09-01)

Antifungal Drug Repurposing
by: Jong H. Kim, et al.
Published: (2020-11-01)

Editorial: Drug Repurposing
by: Pan Pantziarka, et al.
Published: (2019-07-01)

In Silico Screening of Available Drugs Targeting Non-Small Cell Lung Cancer Targets: A Drug Repurposing Approach
by: Muthu Kumar Thirunavukkarasu, et al.
Published: (2021-12-01)

Panic buying of repurposed drugs for COVID-19 in India: Challenges and the way forward
by: Ramdas Ransing, et al.
Published: (2022-01-01)

Are payers treating orphan drugs differently?
by: Joshua P. Cohen, et al.
Published: (2014-01-01)

Risk and Reward in the Orphan Drug Industry
by: Lo, Andrew W, et al.
Published: (2021)

Risk and Reward in the Orphan Drug Industry
by: Lo, Andrew W, et al.
Published: (2022)

Mechanism of coordinated access to orphan drugs
by: DeRidder R, et al.
Published: (2012-11-01)

Orphan drug: Development trends and strategies
by: Aarti Sharma, et al.
Published: (2010-01-01)

Patient access to orphan drugs in France
by: Marion Bourdoncle, et al.
Published: (2019-02-01)

Financing drug discovery for orphan diseases
by: Gromatzky, Austin A., et al.
Published: (2014)

Repurposing therapeutics for COVID-19: Rapid prediction of commercially available drugs through machine learning and docking.
by: Sovesh Mohapatra, et al.
Published: (2020-01-01)

Drug repurposing for cancer therapy
by: Ying Xia, et al.
Published: (2024-04-01)

Repurposed Drugs in Gastric Cancer
by: Diana Araújo, et al.
Published: (2022-12-01)

Drug repurposing with network reinforcement
by: Yonghyun Nam, et al.
Published: (2019-07-01)

Repurposing drugs for the treatment of glioma
by: Chengming Xu, et al.
Published: (2019-01-01)

In silico drug repurposing: An antifungal drug, itraconazole, repurposed as an anticancer agent using molecular docking
by: Sanika Dhorje, et al.
Published: (2020-01-01)